For over 40 years, DiaSorin has been active internationally in the market for in vitro diagnostics and in the immunodiagnostics segment. It develops on an ongoing basis a vast and innovative line of products that are used in analysis laboratories at universities, hospitals and private testing facilities.
The Group is comprised of 24 companies located in Europe, the United States, Central and South America, Asia and South Africa, with almost 1,500 employees (data updated at 06/30/10), 110 of whom work exclusively on research and development projects. Production is carried out at six manufacturing and research facilities located in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater, MN (USA), Dublin (Ireland), Dartford(UK) and Kyalami (South Africa). DiaSorin is present in more than 60 countries with its direct sales network, supported by an international network of over 80 independent distributors.



DiaSorin intends to further strengthen its current competitive position in the global market. The strategy calls for consolidating the Group’s position in the markets where it already operates directly and expanding its direct presence in those areas where such an approach can enable it to benefit more effectively from the market’s growth potential. DiaSorin believes strongly in strengthening its direct presence in all areas with a high growth potential, with the goal of providing its customers with efficient and high quality services.